This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Search for Related Content PubMed PubMed Citation Social Bookmarking                         What's this?

Rationale and design of a clinical trial of a low-molecular-weight heparin in preventing clinically important venous thromboembolism in medical patients: the Prospective Evaluation of Dalteparin efficacy for Prevention of Venous Thromboembolism in Immobilized Patients Trial (the PREVENT study)

The utility of low-molecular-weight heparin (LMWH) in the prophylaxis of venous thromboembolic disease has been examined using the surrogate endpoint of venographically identified thrombi. The largest portion of these thrombi were asymptomatic calf-vein thrombi. The clinical relevance of this observation is a matter of debate. The present study is designed to evaluate the impact of an LMWH on clinically important endpoints.

The current study is a randomized, prospective, double-blinded, multicenter, multinational, controlled clinical trial comparing dalteparin with placebo in moderately high-risk hospitalized medical patients. A total of 3300 patients will be randomized to receive either 5000 IU per day of dalteparin or placebo for 14 days. Patients will undergo appropriate evaluation for any symptomatic episodes and all patients will undergo a bilateral compression ultrasound (CUS) on day 21 to search for asymptomatic proximal thrombi.

The primary endpoint is the combination of objectively confirmed symptomatic deep vein thrombi (DVT), fatal or non-fatal pulmonary emboli, all proximal DVT, and sudden death.

This study will be the first study to examine clinically important endpoints in evaluating the effect of a LMWH in hospitalized medical patients. This study also is the first study to use CUS rather than venography in concordance with contemporary medical practice. This trial is thus designed to address this important question in a clinically relevant manner.

Key Words: dalteparin • deep vein thrombosis • prophylaxis • pulmonary embolism • venous thromboembolism

Vascular Medicine, Vol. 7, No. 4, 269-273 (2002)
DOI: 10.1191/1358863x02vm449oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. D. Paauw, H. Borders, N. Ingalls, S. Boomstra, S. Lambke, B. Fedeson, A. Goldsmith, and A. T. Davis The Incidence of PICC Line-Associated Thrombosis With and Without the Use of Prophylactic Anticoagulants JPEN J Parenter Enteral Nutr, July 1, 2008; 32(4): 443 - 447. [Abstract] [Full Text] [PDF]

				A. T. Cohen, A. G.G. Turpie, A. Leizorovicz, C.-G. Olsson, P. T. Vaitkus, and S. Z. Goldhaber Thromboprophylaxis with dalteparin in medical patients: which patients benefit? Vascular Medicine, May 1, 2007; 12(2): 123 - 127. [Abstract] [PDF]

				F. Dentali, J. D. Douketis, M. Gianni, W. Lim, and M. A. Crowther Meta-analysis: Anticoagulant Prophylaxis to Prevent Symptomatic Venous Thromboembolism in Hospitalized Medical Patients Ann Intern Med, February 20, 2007; 146(4): 278 - 288. [Abstract] [Full Text] [PDF]

				A. G G Turpie and A. Leizorovicz Prevention of venous thromboembolism in medically ill patients: a clinical update Postgrad. Med. J., December 1, 2006; 82(974): 806 - 809. [Abstract] [Full Text] [PDF]

				N. Kucher, A. Leizorovicz, P. T. Vaitkus, A. T. Cohen, A. G. G. Turpie, C.-G. Olsson, S. Z. Goldhaber, and for the PREVENT Medical Thromboprophylaxis Study G Efficacy and Safety of Fixed Low-Dose Dalteparin in Preventing Venous Thromboembolism Among Obese or Elderly Hospitalized Patients: A Subgroup Analysis of the PREVENT Trial Arch Intern Med, February 14, 2005; 165(3): 341 - 345. [Abstract] [Full Text] [PDF]

				A. Leizorovicz, A. T. Cohen, A. G.G. Turpie, C.-G. Olsson, P. T. Vaitkus, S. Z. Goldhaber, and for the PREVENT Medical Thromboprophylaxis Study G Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients Circulation, August 17, 2004; 110(7): 874 - 879. [Abstract] [Full Text] [PDF]